Company: ARTL
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001640334-25-001429
Chunk: 387

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 387
---

 3Table of Contents

ARTELO BIOSCIENCES, INC.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except per share data)

  Three months ended  Six months ended   June 30,  June 30,   2025  2024  2025  2024              OPERATING EXPENSES            General and administrative $1,279  $827  $2,274  $1,909 Research and development  1,871   1,685   3,255   3,192 Total Operating Expenses  3,150   2,512   5,529   5,101                  Loss from Operations  (3,150)  (2,512)  (5,529)  (5,101)                 OTHER INCOME (EXPENSE)                Interest income  1   -   8   - Interest expense  (72)  -   (72)  - Net change in fair value of trading marketable securities  -   79   -   185 Total other income  (71)  79   (64)  185                  Provision for income taxes  -   -   -   -                  NET LOSS $(3,221) $(2,433) $(5,593) $(4,916)                 OTHER COMPREHENSIVE INCOME (LOSS)                Foreign currency translation adjustments  (68)  -   (93)  - Total Other Comprehensive Income (Loss)  (68)  -   (93)  -                  TOTAL COMPREHENSIVE LOSS $(3,289) $(2,433) $(5,686) $(4,916)                 Basic and Diluted Loss per Common Share $(5.61) $(4.52) $(9.80) $(9.17)                 Basic and Diluted Weighted Average Common Shares Outstanding  574   538   571   536 

 4Table of Contents

ARTELO BIOSCIENCES, INC.

Consolidated Statements